Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer

Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in advanced breast cancer.

OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).

Its combination with the Pfizer breast cancer drug will be assessed in the treatment of patients having recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Sean P. Bohen – President and CEO of Olema Oncology said: “This agreement with Pfizer represents continued momentum toward our goal of advancing the clinical development of OP-1250.

“We look forward to learning more about the potential of OP-1250 in combination with palbociclib in patients living with breast cancer.”

As per the terms of the non-exclusive agreement, Olema Oncology is responsible for carrying out the clinical trial, while Pfizer holds the responsibility of providing its study drug.

Olema Oncology is a California-based biopharma company focused on developing targeted therapies for women’s cancers. In July 2020, the company raised $54 million in a Series B financing round, which was co-led by BVF Partners, Janus Henderson Investors, and Logos Capital.